Butylphthalide
Phase 3Small molecule
Butylphthalide is one of 212 small molecule programs targeting Ischemic stroke. It is currently in Phase 3.
5
Indications
9
Total Trials
6
Active Trials
211
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
150 competitors in Stroke
#DrugCompanyPhaseTrials
1Butylphthalide
PPeking Union Medical College Hospital
Phase 3
Zometa
PfizerPreclinical
Savella
AbbViePreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemic stroke3 trials
Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment
Completed·—·Phase 3·NCT03539445·1,216 enrolled
Stroke2 trials
Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)
Not yet recruiting·—·Phase 3·NCT07252544·3,156 enrolled
Cognitive impairment1 trial
Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy
Recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT07193277·220 enrolled
ART1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Butylphthalide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details